Debug Stats | ### Total Build Time: 64 ms 55.994 KB CONCEPT_NAME gt=3 ms Completed: 3 ms rowSize= 390 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 306 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=35 ms Completed: 35 ms rowSize= 15.674 KBCONCEPT_GENES gt=21 ms Completed: 21 ms rowSize= 38.391 KBCONCEPT_XREFS gt=4 ms Completed: 4 ms rowSize= 1.180 KBCONCEPT_ANCILLARY gt=1 ms Completed: 1 ms rowSize= 14 bytes- Reload Stats
|
Genes (79)
Species: human : 79 | |
Human | CD24 | 100133941 | CD24 molecule | CD24 expression in clear cell renal cell carcinoma may be associated with high nuclear grade, large tumor size, and shortened progression-free survival | Human | STRA13 | 201254 | stimulated by retinoic acid 13 | Introduction of wild type VHL transgene into clear cell renal carcinoma restored low level expression of STRA13. | Human | FLCN | 201163 | folliculin | | Human | DIRC2 | 84925 | disrupted in renal carcinoma 2 | | Human | RASSF5 | 83593 | Ras association (RalGDS/AF-6) domain family member 5 | The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. By positional cloning, we identified two breakpoint-spanning genes in a familial clear cell renal cell carcinoma (CCRCC)-associated t(1;3)(q32.1;q13.3): LSAMP and NORE1 (RASSF1 homolog). | Human | CD276 | 80381 | CD276 molecule | Both tumor cell and tumor vasculature B7-H3 expression convey important information to predict clear cell renal cell carcinoma outcomes | Human | MUC3B | 57876 | mucin 3B, cell surface associated | In renal carcinoma, we showed a heterogeneous expression of MUC1 and MUC3 with an over-expression of MUC3 in renal clear cell carcinoma. CONCLUSIONS: The results of this study demonstrate that MUC3 and VEGF are overexpressed in renal clear cell carcinoma, and the MUC3 expression ratio is greater in nuclear grade 3 than in grades 1 and 2 (low grades) tumor. Quantitative RT-PCR assay for MUC3 and VEGF mRNA in renal clear cell carcinoma: relationship with nuclear grade and prognosis. In the kidney, MUC3 is expressed in normal convoluted tubules and in renal clear cell carcinoma. | Human | SEMA6A | 57556 | sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A | Sema 6A-1 transcript was also expressed in the majority of renal clear cell carcinoma (RCC) cell lines and to a lesser extent in endothelial cells. | Human | NDRG2 | 57447 | NDRG family member 2 | NDRG2 might play an important role in the carcinogenesis and development of clear cell renal cell carcinoma and may function as a tumor suppressor in clear cell renal cell carcinoma | Human | C3orf10 | 55845 | | Von Hippel-Lindau (VHL) locus deletion of the HSPC300 actin regulator gene greatly lowers risk of clear cell renal cell carcinoma development in Spanish VHL syndrome patients studied | Human | ANGPTL4 | 51129 | angiopoietin-like 4 | We observed particularly high levels of ANGPTL4 mRNA in tumor cells of conventional renal cell carcinoma. This protein is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. | Human | HAVCR1 | 26762 | hepatitis A virus cellular receptor 1 | is expressed at higher levels in clear cell renal cell carcinoma | Human | AMACR | 23600 | alpha-methylacyl-CoA racemase | Immunohistochemistry demonstrated strong AMACR positivity in all cases of papillary renal cell carcinomas (41 of 41, 100%), including 6 metastatic papillary renal cell carcinomas, but only focal or weak reactivity in the minority (18 of 124, 15%) of other renal tumors including 13 of 52 clear cell renal cell carcinomas, 3 of 20 oncocytomas, and 2 of 17 urothelial carcinomas. | Human | RNF139 | 11236 | ring finger protein 139 | | Human | RASSF1 | 11186 | Ras association (RalGDS/AF-6) domain family member 1 | Hypermethylation of the RASSF1A tumor suppressor gene is associated with clear cell renal cell carcinoma | Human | SPINT2 | 10653 | serine peptidase inhibitor, Kunitz type, 2 | Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma. | Human | IGF2BP3 | 10643 | insulin-like growth factor 2 mRNA binding protein 3 | IMP3 over expression was associated with metastatic progression and death for patients with clear cell renal cell carcinoma | Human | MSLN | 10232 | mesothelin | an immunohistochemical panel including CK7,CD10 and mesothelin is optimal for distinguishing between ovarian and renal clear cell carcinoma | Human | BHLHE40 | 8553 | basic helix-loop-helix family, member e40 | Introduction of wild type VHL transgene into clear cell renal carcinoma restored low level expression of STRA13. | Human | CUL2 | 8453 | cullin 2 | Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. | Human | CXCR4 | 7852 | chemokine (C-X-C motif) receptor 4 | An analysis of clear cell renal carcinoma that manifests mutation of the VHL gene in most cases revealed an association of strong CXCR4 expression with poor tumour-specific survival. | Human | BTG2 | 7832 | BTG family, member 2 | Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. | Human | VHL | 7428 | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase | HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma role for VHL mutations promoting conventional clear cell renal cell carcinoma development by an impairment of HIF-1alpha proteolysis Inactivation of the VHL tumor suppressor gene is a genetic change in the tumorigenic pathway of clear-cell renal cell carcinoma and may occur at an early or first step in the tumorigenic pathway rather than as a late event von Hippel-Lindau tumor suppressor protein has a role in clear cell renal carcinoma In Von Hippel-Lindau disease the association of clear cell renal carcinoma development with a relatively high loss of structural stability in pVHL missense-mutants was consistent Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma VHL controls gene expression of TGFBI (BIGH3) and its transactivator KLF10 in renal clear cell carcinoma and other tumors | Human | VBP1 | 7411 | von Hippel-Lindau binding protein 1 | PTHrP is an essential growth factor for clear cell renal carcinoma and is a novel target for the von Hippel-Lindau tumor suppressor protein | Human | TLR3 | 7098 | toll-like receptor 3 | TLR3 is overexpressed in clear cell renal cell carcinoma |
|